Neurocrine Biosciences Inc vs ON Holding AG — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while ON Holding AG trades at $37.31 (market cap $12.55B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals.
| NBIX | ONON | |
|---|---|---|
Market Cap | $17.40B | $12.55B |
Sector | Health | Technology |
52-Week High | $180.55 | $53.21 |
52-Week Low | $123.10 | $31.88 |
Enterprise Value | $16.49B | $11.87B |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →